Bristol-Myers Squibb and Illumina Announce Strategic Collaboration to Develop and Commercialize Companion Diagnostics for Bristol-Myers Squibb’s Oncology Immunotherapies
Illumina, Inc. (ILMN)
Last illumina, inc. earnings: 4/30 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
illumina.com/company/investor-information.html
Company Research
Source: Business Wire
Expands Illumina’s Oncology Offerings for NextSeq™ 550Dx A Diagnostic Version of the Illumina TruSight™ Oncology 500 Assay Will Measure Potentially Predictive Genomic Biomarkers, Including Tumor Mutation Burden NEW YORK & SAN DIEGO--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Illumina, Inc. (NASDAQ: ILMN) today announced a collaboration that will utilize Illumina’s next-generation sequencing (NGS) technology to develop and globally commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb’s oncology portfolio. The companies plan to develop a diagnostic version of the Illumina TruSight Oncology 500 assay to measure potentially predictive genomic biomarkers, including Tumor Mutation Burden (TMB). Illumina’s TruSight Oncology 500 assay is being developed to detect most of the known biomarkers for oncology therapeutics, including TMB and Microsatellite
Show less
Read more
Impact Snapshot
Event Time:
ILMN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ILMN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ILMN alerts
High impacting Illumina, Inc. news events
Weekly update
A roundup of the hottest topics
ILMN
News
- These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar [Yahoo! Finance]Yahoo! Finance
- United States Liquid Biopsy Market Analysis Report 2024: A $3.68 Billion Industry by 2032 from $1.06 Billion in 2023 - Emphasis on Companion Diagnostics, Increasing acceptance of Non-invasive Techniques [Yahoo! Finance]Yahoo! Finance
- Global Targeted Sequencing Industry Research 2023-2033: Burgeoning Opportunities Adoption in Targeted Therapeutics in Oncology and Use in Clinical Research and Trials for Better Disease Pathogenesis [Yahoo! Finance]Yahoo! Finance
- Multicancer Screening Market Projected to Reach $2.72 billion by 2030 - Exclusive Report by 360iResearch [Yahoo! Finance]Yahoo! Finance
- Illumina's planned divestment of GRAIL approved by the European Commission [Yahoo! Finance]Yahoo! Finance
ILMN
Earnings
- 2/8/24 - Beat
ILMN
Sec Filings
- 4/12/24 - Form 8-K
- 4/10/24 - Form 4
- 4/9/24 - Form 8-K
- ILMN's page on the SEC website